- Home
- ATHA vs JUNS Comparison
ATHA vs JUNS Comparison
Compare ATHA & JUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- JUNS
- Stock Information
- Founded
- ATHA 2011
- JUNS 2015
- Country
- ATHA United States
- JUNS United States
- Employees
- ATHA N/A
- JUNS N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- JUNS
- Sector
- ATHA Health Care
- JUNS
- Exchange
- ATHA Nasdaq
- JUNS NYSE
- Market Cap
- ATHA 21.0M
- JUNS 17.6M
- IPO Year
- ATHA 2020
- JUNS 2024
- Fundamental
- Price
- ATHA $0.26
- JUNS $0.61
- Analyst Decision
- ATHA Buy
- JUNS
- Analyst Count
- ATHA 4
- JUNS 0
- Target Price
- ATHA $11.25
- JUNS N/A
- AVG Volume (30 Days)
- ATHA 214.5K
- JUNS 95.3K
- Earning Date
- ATHA 05-09-2025
- JUNS 05-27-2025
- Dividend Yield
- ATHA N/A
- JUNS N/A
- EPS Growth
- ATHA N/A
- JUNS N/A
- EPS
- ATHA N/A
- JUNS N/A
- Revenue
- ATHA N/A
- JUNS N/A
- Revenue This Year
- ATHA N/A
- JUNS N/A
- Revenue Next Year
- ATHA N/A
- JUNS N/A
- P/E Ratio
- ATHA N/A
- JUNS N/A
- Revenue Growth
- ATHA N/A
- JUNS N/A
- 52 Week Low
- ATHA $0.22
- JUNS $0.51
- 52 Week High
- ATHA $3.67
- JUNS $19.51
- Technical
- Relative Strength Index (RSI)
- ATHA 45.40
- JUNS N/A
- Support Level
- ATHA $0.23
- JUNS N/A
- Resistance Level
- ATHA $0.30
- JUNS N/A
- Average True Range (ATR)
- ATHA 0.03
- JUNS 0.00
- MACD
- ATHA 0.00
- JUNS 0.00
- Stochastic Oscillator
- ATHA 37.12
- JUNS 0.00
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.